Aptose Biosciences (TSE:APS) Stock Passes Above Fifty Day Moving Average – Time to Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$2.16 and traded as high as C$2.24. Aptose Biosciences shares last traded at C$2.19, with a volume of 810 shares changing hands.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners cut Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Aptose Biosciences Trading Up 2.3%

The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41. The stock has a market capitalization of C$5.72 million, a price-to-earnings ratio of 3.25 and a beta of -0.46. The business has a 50 day simple moving average of C$2.17 and a 200-day simple moving average of C$1.92.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share for the quarter. As a group, equities analysts expect that Aptose Biosciences Inc. will post -0.59 earnings per share for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.